4 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Cystoscopy, transurethral resection with muscle in the specimen, blue-light or enhanced imaging for carcinoma in situ; re-resection of T1 tumours.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
Single immediate instillation of mitomycin or gemcitabine after resection; surveillance cystoscopy.
The chemotherapy given with radiation to cure anal cancer without surgery, used as a bladder instillation after tumour resection, and since 2020-25 in gel form for upper-tract and recurrent bladder cancers.
A versatile chemotherapy used in pancreatic, bladder, lung, ovarian, breast and biliary cancers, in nasopharyngeal cancer, and as a bladder instillation.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.
Induction and one to three years of maintenance BCG; intravesical chemotherapy when BCG is unavailable; early cystectomy for the highest-risk T1 disease.
Treating early bladder cancer by putting the drug straight into the bladder through a catheter, so the whole body is spared.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
Add these to your appointment list, or take the full question set for this cancer.
Radical cystectomy, or bladder-sparing treatment: pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept with BCG, TAR-200, cretostimogene in trials and early approvals.
Pembrolizumab is an antibody that blocks PD-1. Its U.S. labelled uses depend on cancer, treatment setting and regimen; immune-mediated harms can occur.
Nadofaragene firadenovec is the first gene therapy for bladder cancer: a virus that makes bladder cells produce interferon for weeks, given once every three months.
Nogapendekin alfa inbakicept is an engineered version of the immune-boosting protein IL-15, given with BCG into the bladder, approved in 2024 for early bladder cancer that BCG alone no longer controls.
TAR-200 is a small pretzel-shaped device placed in the bladder that releases gemcitabine for three weeks at a time. It was approved in 2025 for early bladder cancer that no longer responds to BCG.
Cretostimogene is a virus engineered to multiply only in bladder cancer cells with a broken RB pathway, instilled into the bladder. It cleared carcinoma in situ in 75% of BCG-unresponsive patients.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Grade 3+ treatment-related · CS-003: six of 157 patients had study drug-related grade 3 or 4 events. The full text could not be re-read on 17 November 2026; the abstract gives only the commonest such event, micturition urgency in two patients | - | 4% |
| Bladder spasm · CS-003, 157 patients (label): 20% grade 1-2 plus 1% grade 3 | 21% | 1% |
| Micturition urgency · CS-003, 157 patients (label): 19% grade 1-2 plus 1% grade 3 | 20% | 1% |
| Fatigue · CS-003, 157 patients (label) | 24% | 0% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Haematuria · With BCG, QUILT-3.032 cohort A, 88 patients (label) | 32% | 3.4% |
| Dysuria · With BCG, QUILT-3.032 cohort A, 88 patients (label); serious adverse reactions of any kind in 16% | 32% | 0% |
| Urinary frequency · With BCG, QUILT-3.032 cohort A, 88 patients (label) | 27% | 0% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Grade 3+ treatment-related · SunRISe-1 cohort 2, TAR-200 monotherapy (JCO 2025) | - | 12.9% |
| Urinary tract infection · SunRISe-1 cohort 2, monotherapy, 85 patients (label) | 44% | 6% |
| Urinary frequency · SunRISe-1 cohort 2, monotherapy, 85 patients (label) | 48% | 0% |
| Dysuria · SunRISe-1 cohort 2, monotherapy, 85 patients (label) | 42% | 0% |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Grade 3+ treatment-related · BOND-003 cohort C: no grade 3 or 4 treatment-related events | - | 0% |
| Bladder spasm · Treatment-related, BOND-003 cohort C, 112 patients | 25% | - |
| Micturition urgency · Treatment-related, BOND-003 cohort C, 112 patients | 21% | - |
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
Add these to your appointment list, or take the full question set for this cancer.